Oddity raises FY25 adjusted EPS view to $2.10-$2.12 from $2.06-$2.09

Consensus $2.09. Raises FY25 revenue view to $806M-$809M from $799M-$804M, consensus $803.49M. Raises FY25 adjusted EBITDA view to $161M-$163M from $160M-$162M. “We achieved a major milestone this week with the official launch of our newest brand: METHODIQ,” Holtzman continued. “Our goal with METHODIQ is to transform a broken medical care system with precise treatments, pioneering technology, and the highest standard of care. This is the next frontier for ODDITY (ODD), harnessing the power of our data and technology platform to offer medical grade solutions for our users.”